Overview

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

Status:
RECRUITING

Trial end date:
2027-01-31

Target enrollment:

Participant gender:

Summary

To learn if the combination of axicabtagene ciloleucel (axi-cel) and glofitamab as first-line therapy in high-risk LBCL participants or as second-line therapy in LBCL participants can help to control the disease.

Phase:

PHASE2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

Genentech, Inc.
Kite, A Gilead Company

Treatments:

axicabtagene ciloleucel
brexucabtagene autoleucel
glofitamab
obinutuzumab